PDGFRA and gastrointestinal stromal tumor: The clinical benefit was observed for common primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%); meanwhile, PFS was found to be longer for patients with the primary KIT exon 9 mutation.